Relay Therapeutics, Inc.
Clinical trials sponsored by Relay Therapeutics, Inc., explained in plain language.
-
First patients test new 'Smart Bomb' drug for advanced cancers
Disease control Recruiting nowThis is the first study in people to test a new drug called RLY-2608, which is designed to target a specific genetic mutation (PIK3CA) found in many advanced solid tumors and breast cancers. The main goals are to find the safest and most effective dose, check for side effects, an…
Phase: PHASE1 • Sponsor: Relay Therapeutics, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
Targeted drug trial offers hope for rare growth disorders
Disease control Recruiting nowThis study is testing an experimental drug called RLY-2608 in adults and children with rare conditions that cause abnormal tissue overgrowth due to a specific genetic mutation. The research aims to find the right dose, check safety, and see if the drug can reduce the size of over…
Phase: PHASE2 • Sponsor: Relay Therapeutics, Inc. • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
New hope for advanced breast cancer patients after standard treatment fails
Disease control Recruiting nowThis global Phase 3 trial is testing which of two drug combinations works better to control advanced breast cancer that has a specific genetic change (PIK3CA mutation) and has worsened after standard hormone therapy. It will enroll about 540 adults whose cancer has returned or sp…
Phase: PHASE3 • Sponsor: Relay Therapeutics, Inc. • Aim: Disease control
Last updated Mar 11, 2026 14:53 UTC